{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T10:23:04Z","timestamp":1794997384830,"version":"4.9.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Metabolic acidosis (MA) is frequently associated with chronic kidney disease (CKD) progression. Our aim was to compare the effect of oral sodium citrate (SC) with that of oral sodium bicarbonate (SB) on renal function and serum bicarbonate correction, as well as to evaluate their safety profile in patients with MA of CKD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We conducted a prospective, single-center, randomized 1:1, parallel, controlled, unblinded clinical trial of 124 patients with MA and CKD stages 3b and 4. The primary outcome was the mean change in estimated glomerular filtration rate (eGFR). The secondary outcomes were mean change in serum bicarbonate level, eGFR decrease by 30%, eGFR decrease by 50%, dialysis, death or prolonged hospitalization, and a combined endpoint.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>No significant difference was found between the groups in terms of mean eGFR change [adjusted mean difference\u2005=\u2005\u22120.99\u2009mL\/min\/1.73 m<jats:sup>2<\/jats:sup> (95% CI: \u22122.51 to 0.93, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.20)]. We observed a mean serum bicarbonate change of 6.15 mmol\/L [(95% CI: 5.55\u20136.74), <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001] in the SC group and of 6.19 mmol\/L [(95% CI: 5.54\u20136.83), <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001] in the SB group, but no significant difference between the 2 groups [adjusted mean difference\u2005=\u20050.31 mmol\/L (\u22120.22 to 0.85), <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.25]. Cox proportional hazard analysis showed similar risks regarding eGFR decrease by 30% (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.77), eGFR decrease by 50% (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.50), dialysis (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.85), death or prolonged hospitalization (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.29), and combined endpoint (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.57). Study drug discontinuation due to adverse events was significantly more common in the SB group (17.7% vs 4.8%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.02).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>SC and SB have a similar effect on kidney function decline, both improve serum bicarbonate level, but SB is associated with higher rates of medication discontinuation due to adverse events.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000037475","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:06:35Z","timestamp":1709928395000},"page":"e37475","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Sodium citrate versus sodium bicarbonate for metabolic acidosis in patients with chronic kidney disease: A randomized controlled trial"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3574-4635","authenticated-orcid":false,"given":"Bogdan Marian","family":"Sorohan","sequence":"first","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Department of Nephrology, Bucharest, Romania"},{"name":"Fundeni Clinical Institute, Department of Kidney Transplantation, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Obri\u0219c\u0103","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Department of Nephrology, Bucharest, Romania"},{"name":"Fundeni Clinical Institute, Department of Nephrology, Bucharest, Romania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Jurubi\u021b\u0103","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Department of Nephrology, Bucharest, Romania"},{"name":"Fundeni Clinical Institute, Department of Nephrology, Bucharest, Romania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Lupu\u0219oru","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Department of Nephrology, Bucharest, Romania"},{"name":"Fundeni Clinical Institute, Department of Nephrology, Bucharest, Romania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia","family":"Achim","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Department of Nephrology, Bucharest, Romania"},{"name":"Fundeni Clinical Institute, Department of Nephrology, Bucharest, Romania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Andronesi","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Department of Nephrology, Bucharest, Romania"},{"name":"Fundeni Clinical Institute, Department of Nephrology, Bucharest, Romania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgiana","family":"Fr\u0103\u021bil\u0103","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Department of Nephrology, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Berechet","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, Department of Nephrology, Bucharest, Romania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Micu","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, Department of Nephrology, Bucharest, Romania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gener","family":"Ismail","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, Department of Nephrology, Bucharest, Romania"},{"name":"Fundeni Clinical Institute, Department of Nephrology, Bucharest, Romania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.2215\/CJN.07400715","article-title":"Acid-base homeostasis.","volume":"10","author":"Lee Hamm","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline.","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1681\/ASN.2008020159","article-title":"Timing of onset of CKD-related metabolic complications.","volume":"20","author":"Moranne","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s11255-020-02563-2","article-title":"Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer.","volume":"52","author":"Copur","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2215\/CJN.07990520","article-title":"Metabolic acidosis and CKD progression.","volume":"16","author":"Madias","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2215\/CJN.13091118","article-title":"Effects of treatment of metabolic acidosis in CKD: a systematic review and meta-analysis.","volume":"14","author":"Navaneethan","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.xkme.2020.12.006","article-title":"Metabolic acidosis in CKD: a review of recent findings.","volume":"3","author":"Melamed","year":"2021","journal-title":"Kidney Med"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.ajkd.2019.07.016","article-title":"Effects of sodium bicarbonate in CKD stages 3 and 4: a randomized, placebo-controlled, multicenter clinical trial.","volume":"75","author":"Melamed","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1681\/ASN.2008111205","article-title":"Bicarbonate supplementation slows progression of CKD and improves nutritional status.","volume":"20","author":"De Brito-Ashurst","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ki.2009.519","article-title":"Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR.","volume":"77","author":"Phisitkul","year":"2010","journal-title":"Kidney Int"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5049\/EBP.2014.12.2.80","article-title":"Effect of bicarbonate supplementation on renal function and nutritional indices in predialysis advanced chronic kidney disease.","volume":"12","author":"Jeong","year":"2014","journal-title":"Electrolyte Blood Press"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40620-019-00656-5","article-title":"Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study.","volume":"32","author":"Di Iorio","year":"2019","journal-title":"J Nephrol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ekir.2020.12.019","article-title":"A systematic review and meta-analysis on effects of bicarbonate therapy on kidney outcomes.","volume":"6","author":"Hultin","year":"2021","journal-title":"Kidney Int Rep"},{"key":"R14-20250503","first-page":"121","article-title":"Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: a randomized controlled trial.","volume":"35","author":"Dubey","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1681\/ASN.2019070677","article-title":"Mechanisms of metabolic acidosis\u2013induced kidney injury in chronic kidney disease.","volume":"31","author":"Wesson","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/ki.2010.348","article-title":"Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet.","volume":"78","author":"Wesson","year":"2010","journal-title":"Kidney Int"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"F830","DOI":"10.1152\/ajprenal.00587.2010","article-title":"Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone.","volume":"300","author":"Wesson","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/ndt\/gfu388","article-title":"Angiotensin II-mediated GFR decline in subtotal nephrectomy is due to acid retention associated with reduced GFR.","volume":"30","author":"Wesson","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000481892","article-title":"Urine ammonium, metabolic acidosis and progression of chronic kidney disease.","volume":"138","author":"Pourafshar","year":"2018","journal-title":"Nephron"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1172\/JCI112020","article-title":"Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3.","volume":"76","author":"Nath","year":"1985","journal-title":"J Clin Invest"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0272-6386(12)80344-1","article-title":"Increased ammoniagenesis as a determinant of progressive renal injury.","volume":"17","author":"Nath","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1159\/000073019","article-title":"Oxidative stress in a novel model of chronic acidosis in LLC-PK1 cells.","volume":"95","author":"Rustom","year":"2003","journal-title":"Nephron Exp Nephrol"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/ki.2014.83","article-title":"Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate.","volume":"86","author":"Goraya","year":"2014","journal-title":"Kidney Int"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/MNH.0000000000000491","article-title":"Clinical evidence that treatment of metabolic acidosis slows the progression of chronic kidney disease.","volume":"28","author":"Goraya","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:20:32Z","timestamp":1746318032000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037475","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]}}}